DGNMF (Diagnamed Holdings) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)


What is Diagnamed Holdings ROE % Adjusted to Book Value?

Diagnamed Holdings DGNMF +9.03% ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. The stock has 1 warning sign investors should review.

Diagnamed Holdings's ROE % for the quarter that ended in Mar. 2026 was 0.00%. Diagnamed Holdings's PB Ratio for the quarter that ended in Mar. 2026 was N/A. Diagnamed Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

Diagnamed Holdings ROE % Adjusted to Book Value Related Terms

Diagnamed Holdings ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Diagnamed Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diagnamed Holdings ROE % Adjusted to Book Value Chart

Diagnamed Holdings Annual Data
Trend Sep21 Sep22 Sep23 Sep24 Sep25
ROE % Adjusted to Book Value
0.00 0.00 -9.44 0.00 0.00

Diagnamed Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DGNMF vs VEEV, BTSG, TEM: ROE % Adjusted to Book Value Comparison

For the Health Information Services subindustry, Diagnamed Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diagnamed Holdings ROE % Adjusted to Book Value vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diagnamed Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Diagnamed Holdings's ROE % Adjusted to Book Value falls into.


Diagnamed Holdings ROE % Adjusted to Book Value Calculation

Diagnamed Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in Sep. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Diagnamed Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Diagnamed Holdings (DGNMF) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Diagnamed Holdings and its competitors.
Is Diagnamed Holdings' ROE % Adjusted to Book Value too high?
Diagnamed Holdings' current ROE % Adjusted to Book Value is 0.00%.
How does Diagnamed Holdings' ROE % Adjusted to Book Value compare to VEEV and BTSG?
Diagnamed Holdings' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Healthcare Providers & Services company?
A good ROE % Adjusted to Book Value depends on the Healthcare Providers & Services industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Diagnamed Holdings and its competitors. Diagnamed Holdings's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnamed Holdings stock overvalued right now?
Diagnamed Holdings (DGNMF) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Diagnamed Holdings (DGNMF), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Diagnamed Holdings Business Description

Other Exchanges DMED:Canada
Address 82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
Diagnamed Holdings Corp is engaged in developing a platform of software-based prescription digital therapeutic products (PDT Products) with the potential to improve early detection of neurological disorders, overall patient health and lower healthcare costs. Its products include, CERVAI which is a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It is also investigating other technological applications such as BrainAge and BrainTremor.